| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Division of Hematology/Oncology [A. M., F. F., A. K.], Molecular Cardiology Research Institute, New England Medical Center, and Departments of Medicine and Biochemistry, Tufts University School of Medicine [L. K., A. K.], Boston, Massachusetts 02111
Proteases give cancer a defining characteristic of being able to break through extracellular matrix barriers and invade into other tissues in response to chemotactic signals. Recently, the cell surface protease-activated receptor (PAR)-1 has been shown to act as a chemokine receptor in inflammatory cells, and its expression is tightly correlated with metastatic propensity of breast cancer cells. The aim of the present study was to determine whether activation of PAR1 or the other known PARs (PAR2–4) can regulate migration and invasion of breast cancer cells. We found that the highly invasive MDAMB231 breast cancer cell line expressed very high levels of functional PAR1, PAR2, and PAR4, whereas minimally invasive MCF7 cells had trace amounts of PAR1 and low levels of PAR2 and PAR4. Despite the differences in expression, PAR2 and PAR4 acted as chemokine receptors in both invasive and minimally invasive breast cell lines. Quite unexpectedly, we found that activation of PAR1 with thrombin or the peptide agonist SFLLRN markedly inhibited invasion and migration of MDAMB231 cells when applied as a concentration gradient in the direction of cell movement. Additionally, we demonstrated that inhibition of chemotaxis was mediated through a Gi/phosphoinositide-3-OH kinase-dependent pathway. Activation of Gi signaling with epinephrine or wasp venom mastoparan also inhibited invasion and migration of the breast cancer cells. These findings suggest that therapeutics targeted toward Gi-couplers that are selectively expressed in breast cancer cells could prove beneficial in halting the progression of invasive breast cancer.
This article has been cited by other articles:
|
|
 |
|
  E. Yang, A. Boire, A. Agarwal, N. Nguyen, K. O'Callaghan, P. Tu, A. Kuliopulos, and L. Covic Blockade of PAR1 Signaling with Cell-Penetrating Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses Tumor Survival and Metastasis Cancer Res., August 1, 2009; 69(15): 6223 - 6231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wilson, K. C. Nannuru, and R. K. Singh Cathepsin G Recruits Osteoclast Precursors via Proteolytic Activation of Protease-Activated Receptor-1 Cancer Res., April 1, 2009; 69(7): 3188 - 3195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Wilson, R. Harada, L. LeDuy, M. D. Hollenberg, and A. Nepveu CUX1 Transcription Factor Is a Downstream Effector of the Proteinase-activated Receptor 2 (PAR2) J. Biol. Chem., January 2, 2009; 284(1): 36 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Elzer, D. A. Heitzman, M. I. Chernin, and J. F. Novak Differential Effects of Serine Proteases on the Migration of Normal and Tumor Cells: Implications for Tumor Microenvironment Integr Cancer Ther, December 1, 2008; 7(4): 282 - 294. [Abstract] [PDF]
|
|
|
|
|
|
H. H. Versteeg, F. Schaffner, M. Kerver, L. G. Ellies, P. Andrade-Gordon, B. M. Mueller, and W. Ruf Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T Mice Cancer Res., September 1, 2008; 68(17): 7219 - 7227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Agarwal, L. Covic, L. M. Sevigny, N. C. Kaneider, K. Lazarides, G. Azabdaftari, S. Sharifi, and A. Kuliopulos Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2746 - 2757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hatziapostolou, C. Polytarchou, D. Panutsopulos, L. Covic, and P. N. Tsichlis Proteinase-Activated Receptor-1-Triggered Activation of Tumor Progression Locus-2 Promotes Actin Cytoskeleton Reorganization and Cell Migration Cancer Res., March 15, 2008; 68(6): 1851 - 1861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gillibert-Duplantier, V. Neaud, J.-F. Blanc, P. Bioulac-Sage, and J. Rosenbaum Thrombin inhibits migration of human hepatic myofibroblasts Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G128 - G136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nguyen, A. Kuliopulos, R. A. Graham, and L. Covic Tumor-Derived Cyr61(CCN1) Promotes Stromal Matrix Metalloproteinase-1 Production and Protease-Activated Receptor 1-Dependent Migration of Breast Cancer Cells. Cancer Res., March 1, 2006; 66(5): 2658 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Morris, Y. Ding, T. K. Ricks, A. Gullapalli, B. L. Wolfe, and J. Trejo Protease-Activated Receptor-2 Is Essential for Factor VIIa and Xa-Induced Signaling, Migration, and Invasion of Breast Cancer Cells Cancer Res., January 1, 2006; 66(1): 307 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Belting, J. Ahamed, and W. Ruf Signaling of the Tissue Factor Coagulation Pathway in Angiogenesis and Cancer Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1545 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Arribas Matrix Metalloproteases and Tumor Invasion N. Engl. J. Med., May 12, 2005; 352(19): 2020 - 2021. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suganuma, K. Ino, K. Shibata, H. Kajiyama, T. Nagasaka, S. Mizutani, and F. Kikkawa Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination Clin. Cancer Res., April 1, 2005; 11(7): 2686 - 2694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ge, S. K. Shenoy, R. J. Lefkowitz, and K. DeFea Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both {beta}-Arrestin-1 and -2 J. Biol. Chem., December 31, 2004; 279(53): 55419 - 55424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, J. L. Hunt, D. P. Landsittel, S. Muller, K. Adler-Storthz, R. L. Ferris, D. M. Shin, and Z.(G. Chen Correlation of Protease-Activated Receptor-1 With Differentiation Markers in Squamous Cell Carcinoma of the Head and Neck and Its Implication in Lymph Node Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8451 - 8459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hu, M. Lee, W. Campbell, R. Perez-Soler, and S. Karpatkin Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis Blood, November 1, 2004; 104(9): 2746 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Darmoul, V. Gratio, H. Devaud, F. Peiretti, and M. Laburthe Activation of Proteinase-Activated Receptor 1 Promotes Human Colon Cancer Cell Proliferation Through Epidermal Growth Factor Receptor Transactivation Mol. Cancer Res., September 1, 2004; 2(9): 514 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Shi, B. Gangadharan, L. F. Brass, W. Ruf, and B. M. Mueller Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis Mol. Cancer Res., July 1, 2004; 2(7): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-C. Lee, T.-H. Lee, S. Avraham, and H. K. Avraham Involvement of the Chemokine Receptor CXCR4 and Its Ligand Stromal Cell-Derived Factor 1{alpha} in Breast Cancer Cell Migration Through Human Brain Microvascular Endothelial Cells Mol. Cancer Res., June 1, 2004; 2(6): 327 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Hjortoe, L. C. Petersen, T. Albrektsen, B. B. Sorensen, P. L. Norby, S. K. Mandal, U. R. Pendurthi, and L. V. M. Rao Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration Blood, April 15, 2004; 103(8): 3029 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. OSSOVSKAYA and N. W. BUNNETT Protease-Activated Receptors: Contribution to Physiology and Disease Physiol Rev, April 1, 2004; 84(2): 579 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-H. Koo and D.-S. Kim Factor Xa Induces Mitogenesis of Vascular Smooth Muscle Cells via Autocrine Production of Epiregulin, J. Biol. Chem., December 26, 2003; 278(52): 52578 - 52586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. O'Brien, H. Koi, S. Parry, L. F. Brass, J. F. Strauss III, L.-P. Wang, J. E. Tomaszewski, and L. K. Christenson Thrombin Receptors and Protease-Activated Receptor-2 in Human Placentation: Receptor Activation Mediates Extravillous Trophoblast Invasion in Vitro Am. J. Pathol., October 1, 2003; 163(4): 1245 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ge, Y. Ly, M. Hollenberg, and K. DeFea A {beta}-Arrestin-dependent Scaffold Is Associated with Prolonged MAPK Activation in Pseudopodia during Protease-activated Receptor-2-induced Chemotaxis J. Biol. Chem., September 5, 2003; 278(36): 34418 - 34426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Yin, Z. Salah, S. Grisaru-Granovsky, I. Cohen, S. C. Even-Ram, M. Maoz, B. Uziely, T. Peretz, and R. Bar-Shavit Human Protease-Activated Receptor 1 Expression in Malignant Epithelia: A Role in Invasiveness Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mareel and A. Leroy Clinical, Cellular, and Molecular Aspects of Cancer Invasion Physiol Rev, April 1, 2003; 83(2): 337 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sugimoto, N. Takuwa, H. Okamoto, S. Sakurada, and Y. Takuwa Inhibitory and Stimulatory Regulation of Rac and Cell Motility by the G12/13-Rho and Gi Pathways Integrated Downstream of a Single G Protein-Coupled Sphingosine-1-Phosphate Receptor Isoform Mol. Cell. Biol., March 1, 2003; 23(5): 1534 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hollenberg and S. J. Compton International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors Pharmacol. Rev., June 1, 2002; 54(2): 203 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-D. NGUYEN, S. FAIVRE, E. BRUYNEEL, C. RIVAT, M. SETO, T. ENDO, M. MAREEL, S. EMAMI, and C. GESPACH RhoA- and RhoD-dependent regulatory switch of G{alpha} subunit signaling by PAR-1 receptors in cellular invasion FASEB J, April 1, 2002; 16(6): 565 - 576. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
